Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello everyone and welcome to ARCA's Biosciences first quarter 2025 earnings and financial results call. My name's Lydia and I'll be your operator today. After the prepared remarks, there'll be an opportunity to ask questions. If you'd like to participate in the Q&A, you can do so by pressing star followed by one on your telephone keypad. I'll now hand you over to Pia Eates, Vice President of Investor Relations to begin. Please go ahead. Good afternoon, and thank you for joining us on today's conference call to discuss ARGUS's first quarter 2025 financial results and pipeline updates. I'd like to remind you that on this call, management will make forward-looking statements, including statements about our cash runway, our projected 2025 revenue, and our expected clinical development milestones and timelines. All statements, other than historical facts, reflect the current beliefs and expectations of management and involve risks and uncertainties that may cause our actual results to differ from those expressed. Those risks and uncertainties are described in our most recent quarterly report on Form 10-Q that is filed with the SEC. Today you'll hear from our CEO, Terry Rosen, CMO, Richard Marcus, COO, Jennifer Jarrett, and CFO, Bob Gels. We'll also be joined by our President, Juan Jaen, for questions after the prepared remarks. With that, I'll turn it over to Terry. Thanks very much, Pia, and thanks to all of you for listening in today. While the world around us has been somewhat or maybe definitely tumultuous. At Arcus, we've really remained focused on execution, and that execution goes with speed, efficiency, and most importantly, rigor. And so before we get into the details, I want to emphasize three points that will be apparent in our discussion today. So first off, ...